Show simple item record

dc.contributor.authorFriedman, Richard J.
dc.contributor.authorGallus, Alexander
dc.contributor.authorGil-Garay, Enrique
dc.contributor.authorFitzgerald, Gordon
dc.contributor.authorCushner, Fred
dc.date2022-08-11T08:08:08.000
dc.date.accessioned2022-08-23T15:43:37Z
dc.date.available2022-08-23T15:43:37Z
dc.date.issued2010-09-10
dc.date.submitted2011-09-21
dc.identifier.citation<p>Am J Orthop (Belle Mead NJ). 2010 Sep;39(9 Suppl):14-21.</p>
dc.identifier.issn1078-4519 (Linking)
dc.identifier.pmid21290027
dc.identifier.urihttp://hdl.handle.net/20.500.14038/27137
dc.description.abstractThe Global Orthopaedic Registry (GLORY) offers insights into multinational practice patterns of venous thromboembolism (VTE) prophylaxis in orthopedic surgery, based on data from 15,020 patients undergoing primary total knee arthroplasty or primary total hip arthroplasty from 2001 to 2004. Registry data show that the first choice for in-hospital VTE prophylaxis was low-molecular-weight heparin. Multimodal prophylaxis was common. Warfarin was more widely used in the USA than elsewhere in the world. GLORY data suggest that real-world practice often fails to meet the standards for prophylaxis recommended in the American College of Chest Physicians evidence-based guidelines, particularly in the USA. However, many US orthopedic surgeons may follow other practice guidelines, causing an underestimation of prophylaxis us in this study. Warfarin in the USA often failed to achieve recommended target International Normalized Ratio (INR) values. This paper reviews the GLORY practice findings in light of the contemporary literature on best practices for VTE prophylaxis in orthopedic patients.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=21290027&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://mdedge-files-live.s3.us-east-2.amazonaws.com/files/s3fs-public/Document/September-2017/039090014s.pdf
dc.subjectAnticoagulants
dc.subject*Arthroplasty, Replacement, Hip
dc.subject*Arthroplasty, Replacement, Knee
dc.subjectDatabases, Factual
dc.subjectHealth Planning Guidelines
dc.subjectHeparin, Low-Molecular-Weight
dc.subjectHumans
dc.subjectIntermittent Pneumatic Compression Devices
dc.subject*Physician's Practice Patterns
dc.subjectPostoperative Complications
dc.subject*Registries
dc.subjectVenous Thromboembolism
dc.subjectWarfarin
dc.subjectCardiovascular Diseases
dc.subjectHealth Services Administration
dc.subjectHealth Services Research
dc.subjectOrthopedics
dc.subjectPreventive Medicine
dc.titlePractice patterns in the use of venous thromboembolism prophylaxis after total joint arthroplasty--insights from the Multinational Global Orthopaedic Registry (GLORY)
dc.typeJournal Article
dc.source.journaltitleAmerican journal of orthopedics (Belle Mead, N.J.)
dc.source.volume39
dc.source.issue9 Suppl
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/cor_glory/3
dc.identifier.contextkey2249945
html.description.abstract<p>The Global Orthopaedic Registry (GLORY) offers insights into multinational practice patterns of venous thromboembolism (VTE) prophylaxis in orthopedic surgery, based on data from 15,020 patients undergoing primary total knee arthroplasty or primary total hip arthroplasty from 2001 to 2004. Registry data show that the first choice for in-hospital VTE prophylaxis was low-molecular-weight heparin. Multimodal prophylaxis was common. Warfarin was more widely used in the USA than elsewhere in the world. GLORY data suggest that real-world practice often fails to meet the standards for prophylaxis recommended in the American College of Chest Physicians evidence-based guidelines, particularly in the USA. However, many US orthopedic surgeons may follow other practice guidelines, causing an underestimation of prophylaxis us in this study. Warfarin in the USA often failed to achieve recommended target International Normalized Ratio (INR) values. This paper reviews the GLORY practice findings in light of the contemporary literature on best practices for VTE prophylaxis in orthopedic patients.</p>
dc.identifier.submissionpathcor_glory/3
dc.contributor.departmentCenter for Outcomes Reseaerch
dc.source.pages14-21


This item appears in the following Collection(s)

Show simple item record